These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 27400947)

  • 1. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    Smith M; De Bono J; Sternberg C; Le Moulec S; Oudard S; De Giorgi U; Krainer M; Bergman A; Hoelzer W; De Wit R; Bögemann M; Saad F; Cruciani G; Thiery-Vuillemin A; Feyerabend S; Miller K; Houédé N; Hussain S; Lam E; Polikoff J; Stenzl A; Mainwaring P; Ramies D; Hessel C; Weitzman A; Fizazi K
    J Clin Oncol; 2016 Sep; 34(25):3005-13. PubMed ID: 27400947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
    Basch EM; Scholz M; de Bono JS; Vogelzang N; de Souza P; Marx G; Vaishampayan U; George S; Schwarz JK; Antonarakis ES; O'Sullivan JM; Kalebasty AR; Chi KN; Dreicer R; Hutson TE; Dueck AC; Bennett AV; Dayan E; Mangeshkar M; Holland J; Weitzman AL; Scher HI
    Eur Urol; 2019 Jun; 75(6):929-937. PubMed ID: 30528222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
    Morris MJ; Molina A; Small EJ; de Bono JS; Logothetis CJ; Fizazi K; de Souza P; Kantoff PW; Higano CS; Li J; Kheoh T; Larson SM; Matheny SL; Naini V; Burzykowski T; Griffin TW; Scher HI; Ryan CJ
    J Clin Oncol; 2015 Apr; 33(12):1356-63. PubMed ID: 25624432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
    Fizazi K; Jones R; Oudard S; Efstathiou E; Saad F; de Wit R; De Bono J; Cruz FM; Fountzilas G; Ulys A; Carcano F; Agarwal N; Agus D; Bellmunt J; Petrylak DP; Lee SY; Webb IJ; Tejura B; Borgstein N; Dreicer R
    J Clin Oncol; 2015 Mar; 33(7):723-31. PubMed ID: 25624429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.
    Sonpavde GP; Pond GR; Fizazi K; de Bono JS; Basch EM; Scher HI; Smith MR
    Eur Urol Oncol; 2020 Aug; 3(4):540-543. PubMed ID: 31412002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
    Smith MR; Sweeney CJ; Corn PG; Rathkopf DE; Smith DC; Hussain M; George DJ; Higano CS; Harzstark AL; Sartor AO; Vogelzang NJ; Gordon MS; de Bono JS; Haas NB; Logothetis CJ; Elfiky A; Scheffold C; Laird AD; Schimmoller F; Basch EM; Scher HI
    J Clin Oncol; 2014 Oct; 32(30):3391-9. PubMed ID: 25225437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
    Madan RA; Karzai FH; Al Harthy M; Petrylak DP; Kim JW; Arlen PM; Rosner I; Theoret MR; Cordes L; Bilusic M; Peer CJ; Dawson NA; Couvillon A; Hankin A; Williams M; Chun G; Owens H; Marte JL; Lee MJ; Tomita Y; Yuno A; Trepel JB; Lee S; Steinberg SM; Gulley JL; Figg WD; Dahut WL
    BJU Int; 2021 Apr; 127(4):435-444. PubMed ID: 32969563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
    Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI
    JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
    Michaelson MD; Oudard S; Ou YC; Sengeløv L; Saad F; Houede N; Ostler P; Stenzl A; Daugaard G; Jones R; Laestadius F; Ullèn A; Bahl A; Castellano D; Gschwend J; Maurina T; Chow Maneval E; Wang SL; Lechuga MJ; Paolini J; Chen I
    J Clin Oncol; 2014 Jan; 32(2):76-82. PubMed ID: 24323035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
    Sternberg C; Armstrong A; Pili R; Ng S; Huddart R; Agarwal N; Khvorostenko D; Lyulko O; Brize A; Vogelzang N; Delva R; Harza M; Thanos A; James N; Werbrouck P; Bögemann M; Hutson T; Milecki P; Chowdhury S; Gallardo E; Schwartsmann G; Pouget JC; Baton F; Nederman T; Tuvesson H; Carducci M
    J Clin Oncol; 2016 Aug; 34(22):2636-43. PubMed ID: 27298414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
    Goodman OB; Flaig TW; Molina A; Mulders PF; Fizazi K; Suttmann H; Li J; Kheoh T; de Bono JS; Scher HI
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):34-9. PubMed ID: 24080993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
    Leibowitz-Amit R; Pintilie M; Khoja L; Azad AA; Berger R; Laird AD; Aftab DT; Chi KN; Joshua AM
    J Transl Med; 2016 Jan; 14():12. PubMed ID: 26762579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
    Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
    Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients.
    Gu T; Li J; Chen T; Zhu Q; Ding J
    Int Urol Nephrol; 2023 Apr; 55(4):883-892. PubMed ID: 36709467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
    Fay AP; Albiges L; Bellmunt J
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
    Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
    ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study.
    Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP
    Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
    Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Ryan CJ; Smith MR; Fizazi K; Saad F; Mulders PF; Sternberg CN; Miller K; Logothetis CJ; Shore ND; Small EJ; Carles J; Flaig TW; Taplin ME; Higano CS; de Souza P; de Bono JS; Griffin TW; De Porre P; Yu MK; Park YC; Li J; Kheoh T; Naini V; Molina A; Rathkopf DE;
    Lancet Oncol; 2015 Feb; 16(2):152-60. PubMed ID: 25601341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.